ArticlePLoS pathogens2010
Gene annotation and drug target discovery in Candida albicans with a tagged transposon mutant collection.
Article in PLoS pathogens, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis.The Pediatric infectious disease journal · 2013Pooled it
- Candida auris uses nutrient sensing to modulate virulence and host immune responses.Nature microbiology · 2026Article
- Application of the Mutant Libraries forInternational journal of molecular sciences · 2022Review
- High-Throughput Chemical Screen Identifies a 2,5-Disubstituted Pyridine as an Inhibitor of Candida albicans Erg11.mSphere · 2022Article
- Review
- Advances in fungal chemical genomics for the discovery of new antifungal agents.Annals of the New York Academy of Sciences · 2021Review
- DeORFanizing Candida albicans Genes using Coexpression.mSphere · 2021Article
- Model-driven analysis of mutant fitness experiments improves genome-scale metabolic models of Zymomonas mobilis ZM4.PLoS computational biology · 2020Article
- Advances in Molecular Tools and In Vivo Models for the Study of Human Fungal Pathogenesis.Microorganisms · 2020Review
- Overcoming Fungal Echinocandin Resistance through Inhibition of the Non-essential Stress Kinase Yck2.Cell chemical biology · 2020Article
- Broad-spectrum antifungal activities and mechanism of drimane sesquiterpenoids.Microbial cell (Graz, Austria) · 2020Article
- The Role of Secretory Pathways inJournal of fungi (Basel, Switzerland) · 2020Review
- Loss of Arp1, a putative actin-related protein, triggers filamentous and invasive growth and impairs pathogenicity inComputational and structural biotechnology journal · 2020Article
- CRISPR-Based Genetic Manipulation ofFrontiers in genome editing · 2020Review
- The Impact of Gene Dosage and Heterozygosity on The Diploid PathobiontJournal of fungi (Basel, Switzerland) · 2019Review
- Iterative screening methodology enables isolation of strains with improved properties for a FACS-based screen and increased L-DOPA production.Scientific reports · 2019Article
- Transposon insertional mutagenesis inGenome research · 2019Article
- Gene Essentiality Analyzed bymBio · 2018Article
- Candida albicans gains azole resistance by altering sphingolipid composition.Nature communications · 2018Article
- Candida albicans Sfl1/Sfl2 regulatory network drives the formation of pathogenic microcolonies.PLoS pathogens · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Candida albicans is the most common human fungal pathogen, causing infections that can be lethal in immunocompromised patients. Although Saccharomyces cerevisiae has been used as a model for C. albicans, it lacks C. albicans' diverse morphogenic forms and is primarily non-pathogenic. Comprehensive genetic analyses that have been instrumental for determining gene function in S. cerevisiae are hampered in C. albicans, due in part to limited resources to systematically assay phenotypes of loss-of-function alleles. Here, we constructed and screened a library of 3633 tagged heterozygous transposon disruption mutants, using them in a competitive growth assay to examine nutrient- and drug-dependent haploinsufficiency. We identified 269 genes that were haploinsufficient in four growth conditions, the majority of which were condition-specific. These screens identified two new genes necessary for filamentous growth as well as ten genes that function in essential processes. We also screened 57 chemically diverse compounds that more potently inhibited growth of C. albicans versus S. cerevisiae. For four of these compounds, we examined the genetic basis of this differential inhibition. Notably, Sec7p was identified as the target of brefeldin A in C. albicans screens, while S. cerevisiae screens with this compound failed to identify this target. We also uncovered a new C. albicans-specific target, Tfp1p, for the synthetic compound 0136-0228. These results highlight the value of haploinsufficiency screens directly in this pathogen for gene annotation and drug target identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.